Breast cancer is the leading cause of cancer mortality among women and these patients are under the risk of developing metastases. The heterogeneous nature of these metastases makes it difficult not only the definition of healing, as well as the risk factors for its development. Currently, some prognostic markers already assist clinical practice, and the most used are hormone receptors (ER and PR), Her2, Ki-67 antigen and Carbohydrate Antigen 15-3 and carcinoembryonic (CEA and CA 15-3). It is known that tumor cells are highly glycolytic, produce lactate and thrive in excess in hypoxic conditions, resulting in acidosis, a reduction in extracellular pH. One of the most important mechanisms involved in the regulation of intracellular pH is concurrent lactate and proton transport mediated by a family of proteins known as monocarboxylate transporter, MCT. Currently, a list of metabolic targets for anticancer therapies includes the MCT1 and MCT4, members of the MCT family regulated by CD147. This project aims to study the expression of MCT1, MCT4 and CD147 by qPCR in tumor samples and in the mononuclear fraction of the peripheral blood of patients with breast cancer during treatment to evaluate their potential prognostic value.
News published in Agência FAPESP Newsletter about the scholarship: